Accelmed closes $400M healthtech fund
March 18, 2021- Share:
Accelmed Partners has closed its second flagship fund on a hard cap of $400 million, passing its original $300 million target. The Florida-based PE firm focuses on backing commercial-stage healthtech companies in the lower middle market. Accelmed has made two investments out of the vehicle thus far, acquiring ocular surface diagnostics company TearLab and leading a funding round in NeuroPace, a developer of brain technology to treat neurological disorders.
- Share:
-
-
-
-